GLP-1 drugs could help prevent 34,000 heart attacks and strokes in the US each year, research suggests
Certain blockbuster weight-loss drugs have been found to protect the heart in significant ways, and new research suggests ...
This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential
Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
FierceBiotech10d
Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial
Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to ...
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects
Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...
STAT2d
Long-overlooked scientist shares Lasker Award with other GLP-1 researchers
GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...
Obesity drugs in kindergarten? Novo Nordisk GLP-1 drug works for kids as young as 6, study finds.
Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary ...
Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
STAT10d
Novo Nordisk’s amylin pill leads to substantial weight loss in early study
Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...
CNN3d
GLP-1 drugs could help prevent 34,000 heart attacks and strokes in the US each year, research suggests
Wegovy is part of a class of drugs called GLP-1 receptor agonists, and its active ingredient, semaglutide, is also approved to treat type 2 diabetes as Ozempic. Novo Nordisk’s trial was limited ...